AlphAIAlphAI — Financial news for AI agents
stocktitan.net$STAA

Third-quarter results from STAAR Surgical are scheduled for release after markets close Nov. 4.

STAAR Surgical (NASDAQ: STAA) will release its third-quarter 2026 financial results after markets close on Nov. 4. A webcast is scheduled for 5:30 p.m. ET, with a replay available for 90 days. Investors can submit questions in advance. STAAR is a global leader in implantable phakic intraocular lenses, with over 4 million ICLs sold in 85 countries.

Original reporting
stocktitan.net
Published Oct 21, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$STAA
Neutral
high confidence
Mentioned
$STAA
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$STAANeutralLow
01

Why it matters

The announcement is informational; no financial metrics or guidance are provided, so immediate market reaction is unlikely.

02

Market read

Provides investors with the schedule for the upcoming earnings release; actionable for timing trades around the release.

03

What to watch

Potential impact of any unexpected guidance or surprise results when released.

Relevance 4/10Novelty 3/10Timing: after-market close on Nov 4

Background

STAAR Surgical (NASDAQ: STAA) is a leading provider of implantable phakic intraocular lenses. The company announced the date and webcast details for its Q3 2026 earnings release.

Company-level read

Ticker impact

$STAANeutralHigh confidence
Context

STAAR Surgical scheduled its Q3 2026 earnings release after markets close on November 4, 2026.

Expected impact

no immediate price impact expected

Evidence & confidence

The article only provides the webcast date and time; without numbers or guidance, the market is unlikely to move until the actual results are released.

Market effects

Sector

None disclosed; the announcement pertains only to STAAR Surgical.

Regional

Limited to investors tracking the company's earnings schedule.

Global

Minimal; no broader market effect anticipated.

Counterpoint

What could challenge this read

Some traders may view the timing as an opportunity to position ahead of the earnings surprise.

Key entities

  • company
    STAAR Surgical

    NASDAQ-listed ophthalmic device manufacturer.

Read at source← All news

Related articles

$STAAHighAI 8/10

STAAR Surgical (STAA) Q3 2026 Earnings Call Transcript

STAAR Surgical (STAA) reported Q3 2026 revenue growth of 31% excluding prior-year adjustments, driven by EVO+ lens adoption in China and global market expansion. Gross margin was impacted by temporary factors but is expected to improve. The company announced a $50M share repurchase program and plans for new product trials. Asia Pacific, EMEA, and Americas regions showed varied growth, with China being the largest market.

finance.yahoo.com
$STAAHigh

STAAR Surgical Reports Third Quarter 2026 Results

STAAR SURGICAL CO (STAA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 STAAR Surgical Reports Third Quarter 2026 Results Net Sales of $83.4 Million in the Third Quarter Net Income of $5.6 Million, with GAAP EPS of $0.11 Adjusted EBITDA [1] of $14.4 Million, or $0.28 per Diluted Share Record Revenue of $270.5 Million in the First Three Q

SEC EDGAR 8-K
$STAAMedAI 9/10

Overseas Investors, Local Philanthropy

SoftBank Group is in early talks to acquire Allied Universal for $30B ($18B equity, $12B debt). Allied, with $22.6B revenue, is a security firm with 800,000 employees. SoftBank's interest aligns with its AI and robotics ambitions, according to Reuters. Allied's CEO Steve Jones has focused on tech advances, including robotics. SoftBank's local investments include Sprint Corp. and Kingston Technology, with mixed outcomes.

ocbj.com
$STAAHigh

Why Staar Surgical Zoomed Almost 8% Higher on Tuesday

Staar Surgical (STAA) shares rose nearly 8% after Stifel's Thomas Stephan upgraded the stock to buy from hold, raising the price target to $31. He cited positive sales momentum, particularly in China, and potential for acquisitions. The company's FDA-approved products and lean operations were also highlighted.

aol.com